Fig. 2From: A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trialFlow chart for the management of tumour regrowth after initial deferral of surgeryBack to article page